Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 4,761,905 shares of Cardiff Oncology, Inc. common stock issuable upon exercise of warrants, representing 5.8% of the class as of September 30, 2026.
Key Highlights
- Reporting person: Highbridge Capital Management, LLC, a Delaware limited liability company and investment adviser to the Highbridge Funds.
- Shares reported: 4,761,905 shares of common stock, par value $0.0001 per share, issuable upon exercise of warrants directly held by the Highbridge Funds.
- Ownership percentage: 5.8% of the class, calculated based on 77,795,249 shares outstanding as of August 26, 2026.
- Voting and dispositive power: Highbridge reported sole voting power and sole dispositive power over all 4,761,905 shares, with zero shared voting or dispositive power.
- Triggering event date: September 30, 2026, identified as the date of the event requiring the filing.
- Share count basis: The outstanding share figure was drawn from Cardiff Oncology's Definitive Proxy Statement on Schedule 14A, filed with the SEC on August 26, 2026.
Highbridge Capital Crosses 5% Threshold in Cardiff Oncology via Warrant Holdings
According to the Schedule 13G filed on November 16, 2026, Highbridge Capital Management, LLC reported beneficial ownership of 4,761,905 shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) common stock. The filing states that these shares are not currently outstanding but are "issuable upon exercise of warrants directly held by the Highbridge Funds," the investment funds and accounts for which Highbridge serves as investment adviser.
The filing reports that the percentage of class, 5.8%, was calculated using an aggregate of 77,795,249 shares of common stock outstanding as of August 26, 2026, as reported in Cardiff Oncology's Definitive Proxy Statement on Schedule 14A, and assumes the exercise of the warrants held by the Highbridge Funds. Highbridge's principal business office is listed as 390 Madison Avenue, 28th Floor, New York, NY 10017. Cardiff Oncology's principal executive offices are located at 11055 Flintkote Avenue, San Diego, California 92121, according to the filing.
The filing notes that the Highbridge Funds "have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein." The filing also includes a certification, signed by Kirk Rule, Executive Director, stating that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
What Was Disclosed
Highbridge Capital Management, LLC disclosed beneficial ownership of 4,761,905 warrant-linked shares of Cardiff Oncology common stock, equaling 5.8% of the class, in a Schedule 13G filed November 16, 2026, with a triggering event date of September 30, 2026.




Please wait processing your request...